Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Solara Active Pharma approves rights issue of Rs. 450 Cr

The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.

BDR Pharma's Nilotinib sets a new standard in the treatment of Philadelphia Chromosome-positive leukaemia

Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

GSK receives USFDA Fast Track designation for investigational vaccine against gonorrhoea

Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries

Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler

This product will be manufactured at Lupin's Pithampur facility in India